Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-FR Version v4-EN
Language French English
Date Updated 2024-04-17 2024-04-17
Drug Identification Number 02357666 02357666
Brand name VIMPAT VIMPAT
Common or Proper name Vimpat IV 10mg/mL Vimpat IV 10mg/mL
Company Name UCB CANADA INC UCB CANADA INC
Ingredients LACOSAMIDE LACOSAMIDE
Strength(s) 10MG 10MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 5 Vials 5 Vials
ATC code N03AX N03AX
ATC description ANTIEPILEPTICS ANTIEPILEPTICS
Reason for shortage Requirements related to complying with good manufacturing practices. Requirements related to complying with good manufacturing practices.
Anticipated start date 2024-04-15 2024-04-15
Actual start date 2024-04-10 2024-04-10
Estimated end date 2024-04-17 2024-04-17
Actual end date 2024-04-16 2024-04-16
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments No risk to product integrity, patient safety or patient access. Delay in release due to QA operations change. No risk to product integrity, patient safety or patient access. Delay in release due to QA operations change.
Health Canada comments